Latest Lipodystrophy Stories
AHMEDABAD, India, May 29, 2014 /PRNewswire/ -- Commences Phase III trials of Lipaglyn(TM) (Saroglitazar) in patients suffering from Lipodystrophy Exploring
Patients, Researchers, Industry and Leading Medical Experts Join Forces to Gain Patient Population Information San Mateo, CA (PRWEB) March 04, 2014 PatientCrossroads,
SAN DIEGO, June 4, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc.
SAN DIEGO, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S.
ROCKLAND, Mass., Nov. 11, 2010 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that the U.S.
SILVER SPRING, Md., Nov. 10 /PRNewswire-USNewswire/ -- The U.S.
Theratechnologies (TSX: TH) announced today that new 26-week data from a combined analysis of both its Phase 3 clinical trials testing tesamorelin in HIV-associated lipodystrophy were presented as a poster (Poster Number 19) at the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, in London, England.
Theratechnologies (TSX: TH) today announced positive data related to body image for patients treated with tesamorelin in both its first and confirmatory Phase 3 clinical trials, in two poster presentations at the XVII International AIDS Conference in Mexico City, Mexico.